Silibinin in Association With Concomitant Chemoradiotherapy and Maintenance Temozolomide in STAT3 Positive IDH Wild-type, Newly Diagnosed Glioblastoma Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

110 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-11-12

Study Completion Date

2027-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Multicenter, double-blind, placebo-controlled, randomized trial.

Patients affected by STAT3 positive newly diagnosed glioblastoma will be eligible. Patients are randomized using a stratified block randomization method with a 1:1 ratio in two arms:

• Experimental/Control arm: Concomitant radiotherapy (60 gy in 30 fractions) + temozolomide 75mg/mq + silibinin/placebo 2 sachets/day dissolved in water throughout concomitant treatment followed by temozolomide cp, 150 mg/m2-200mg/m2, g1-5 q28d + silibinin/placebo 2 sachets/day dissolved in water, day 1-28, q28d for 6-12 cycles. Silibinin/Placebo may be continued until disease progression at the discretion of the physician.

Patients will be stratified based on:

* Type of surgery (complete Vs partial)
* MGMT methylation status (methylated Vs non-methylated)
* ECOG PS (0-1 Vs 2)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma

NCT01062425

Adult Glioblastoma Adult Gliosarcoma

COMPLETED PHASE2

Neoadjuvant Radio-chemotherapy Safety Pilot Study in Patients With Glioblastoma

NCT06418113

Glioblastoma Glioblastoma Multiforme Glioblastoma, IDH-wildtype +2 more

RECRUITING PHASE1

Prospective Double Arm Randomized Trial: WBRT Alone and WBRT Plus Silibinin

NCT05793489

Brain Metastases, Adult

ACTIVE_NOT_RECRUITING NA

Elective Simultaneous Modulated Accelerated Brain Radiation Therapy for NSCLCs With Limited Brain Metastases

NCT03414944

Brain Metastases

UNKNOWN NA

A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma

NCT01878617

Medulloblastoma

ACTIVE_NOT_RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glioblastoma IDH Wild-type and STAT3-positive Glioblastoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Silbrain_Experimental Arm

Concomitant radiotherapy (60 gy in 30 fractions) + temozolomide 75mg/mq + silibinin 2 sachets/day dissolved in water throughout concomitant treatment followed by temozolomide cp, 150 mg/m2-200mg/m2, g1-5 q28d + silibinin 2 sachets/day dissolved in water, day 1-28, q28d for 6cycles. Silibinin will be continued until disease progression or up to 24 months. In patients who develop progression during temozolomide treatment, administration of silibinin will be continued for up to 6 months after the last dose of temozolomide.

Group Type EXPERIMENTAL

Silibinin as STAT3 inhibitor

Intervention Type DIETARY_SUPPLEMENT

Sillbrain will be available as granulate in sachets of 3.7g and it will be administered twice a day during chemo-radiotherapy and day 1-28 in maintenance phase every cycle. Each 3.7 g sachet of Sillbrain contains 500 mg silibinin. Every patient will assume 2 sachets/day for a total of 1 g/day of silibinin.

Placebo_Control Arm

Concomitant radiotherapy (60 gy in 30 fractions) + temozolomide 75mg/mq + placebo 2 sachets/day dissolved in water throughout concomitant treatment followed by temozolomide cp, 150 mg/m2-200mg/m2, g1-5 q28d + placebo 2 sachets/day dissolved in water, day 1-28, q28d for 6 cycles. Silibinin/Placebo may be continued until disease progression at the discretion of the physician. Silibinin/Placebo will be continued until disease progression or up to 24 months. In patients who develop progression during temozolomide treatment, administration of silibinin (or placebo) will be continued for up to 6 months after the last dose of temozolomide.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Placebo will be available as granulate in sachets of 3.7g and it will be administered twice a day during chemo-radiotherapy and day 1-28 in maintenance phase every cycle. Every patient will assume 2 sachets/day for a total of 1 g/day of placebo.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Silibinin as STAT3 inhibitor

Sillbrain will be available as granulate in sachets of 3.7g and it will be administered twice a day during chemo-radiotherapy and day 1-28 in maintenance phase every cycle. Each 3.7 g sachet of Sillbrain contains 500 mg silibinin. Every patient will assume 2 sachets/day for a total of 1 g/day of silibinin.

Intervention Type DIETARY_SUPPLEMENT

Placebo

Placebo will be available as granulate in sachets of 3.7g and it will be administered twice a day during chemo-radiotherapy and day 1-28 in maintenance phase every cycle. Every patient will assume 2 sachets/day for a total of 1 g/day of placebo.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* New histologically confirmed diagnosis of glioblastoma (WHO 2021)
* Local availability of MGMT methylation status
* Immunohistochemical positivity of activated STAT3 (pSTAT3) expression on the tumor tissue sample. STAT3 expression will be evaluated centrally by UOC Anatomia Patologica of Azienda Ospedale Università di Padova.
* Chemoradiotherapy start within 7 weeks from surgery
* Patients without disease progression after surgery
* Availability of paraffin-embedded tumor tissue
* Age ≥18 years
* ECOG PS 0-2; Karnofsky 100-70
* Signing of informed consent prior to any study procedure
* Patients (both males and females) should employ adequate contraceptive measures, which should be maintained during the whole duration of the trial (from screening to 6 months after the last dose of Temozolomide).
* Have adequate bone marrow, liver and kidney function, as measured by the following laboratory assessments conducted within 10 days before the start of study treatment:
* Hemoglobin \> 9.0 g/dl
* Absolute neutrophil count (ANC) ≥1500/mm3 without granulocyte colony-stimulating factor (G-CSF) and other hematopoietic growth factors
* Platelet count ≥100,000/μl
* WBC ≥3.0 x 10 9 /L
* Total bilirubin \<1.5 times the upper limit of normal
* ALT and AST \<3 x the upper limit of normal
* Serum creatinine \<1.5 times the upper limit of normal
* Glomerular filtration rate ≥ 30 mL/min/1.73 m2 according to the abbreviated formula Modified Diet in Renal Disease
* Alkaline phosphatase \<2.5 x ULN
* PT-INR/PTT \<1.5 x upper limit of normal (patients who are therapeutically anticoagulated with anticoagulant drugs will be able to participate provided there is no history of abnormal background in these parameters, based on history).
* Complete urinalysis
* Stable and decreasing corticosteroid dosage in the last 10 days before brain MRI

Exclusion Criteria

* Patients diagnosed with glioblastoma (WHO grade IV 2021) who have only had a diagnostic biopsy
* Chemotherapy, immunotherapy, or antineoplastic therapy for glioblastoma
* Negative immunohistochemistry of STAT3 expression on the tumor tissue sample
* Diagnosis of another tumor or secondary brain localization
* In the investigator's judgment, any evidence of severe or uncontrolled systemic disease including: uncontrolled hypertension; hemorrhagic diathesis; active infection with HBV, HCV, HIV. Screening for such chronic conditions is not required by the protocol; bone marrow reserve or organ dysfunction as demonstrated by laboratory tests.
* Patients who are unable to comply with study procedures and requirements.
* Contraindication to Brain MRI
* Pregnant or breastfeeding patients
* Patients who are unable to swallow capsules or sachets dissolved in water.
* Patient unable to sign the Informed Consent
* Glioblastoma leptomeningeal dissemination
* Congestive heart failure classified as New York Heart Association (NYHA) Class 2 or higher; Unstable angina (symptoms of angina at rest) or new onset angina ≤3 months prior to screening; myocardial infarction \<6 months prior to 'start of study treatment; cardiac arrhythmias requiring antiarrhythmic therapy, with the exception of beta-blockers or digoxin; uncontrolled hypertension (systolic blood pressure \[SBP\]\>140 mmHg or diastolic blood pressure \[DBP\] \>90 mmHg) despite optimal medical management.
* Arterial thrombotic or embolic events such as stroke and/or transient ischemic attacks) or
* Pulmonary embolism in the 6 months prior to the start of study treatment
* Ongoing infection with grade 2 or higher severity (NCI-CTCAE v 5.0)
* Known history of human immunodeficiency virus (HIV) infection; hepatitis B or C active or chronic requiring treatment with antiviral therapy
* History of organ allotransplantation
* Evidence or history of any bleeding diathesis (including mild hemophilia), regardless of its severity;
* Injuries, ulcers or bone fractures that have not fully resolved.
* Renal failure requiring hemodialysis or peritoneal dialysis
* Presenting interstitial lung disease with ongoing signs and symptoms at the time informed consent is obtained.
* Persistent proteinuria \>3.5 g/24 hours as measured by urinary protein-creatinine ratio from a urine sample (≥ Grade 3, NCI-CTCAE v 5.0). CTCAE 5.0 is also available in Appendix 1.

Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.